Novavax (NVAX) Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

Does the media prefer BCRX or NVAX?

In the previous week, Novavax had 25 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 34 mentions for Novavax and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.92 beat Novavax's score of 0.92 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	19 Very Positive mention(s)	9 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BCRX or NVAX more profitable?

BioCryst Pharmaceuticals has a net margin of -30.01% compared to Novavax's net margin of -32.18%.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-30.01%	N/A	-24.06%
Novavax	-32.18%	N/A	-17.05%

Do analysts rate BCRX or NVAX?

BioCryst Pharmaceuticals presently has a consensus target price of $16.56, indicating a potential upside of 60.19%. Novavax has a consensus target price of $19.00, indicating a potential upside of 142.59%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Novavax	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Which has more risk and volatility, BCRX or NVAX?

BioCryst Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Novavax has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in BCRX or NVAX?

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor BCRX or NVAX?

Novavax received 353 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 74.00% of users gave Novavax an outperform vote while only 67.12% of users gave BioCryst Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
BioCryst Pharmaceuticals	Outperform Votes 498 67.12%	Underperform Votes 244 32.88%
Novavax	Outperform Votes 851 74.00%	Underperform Votes 299 26.00%

Which has stronger earnings and valuation, BCRX or NVAX?

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Novavax. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$503.49M	4.30	-$226.54M	-$0.26	-39.75
Novavax	$1.21B	1.04	-$545.06M	$2.65	2.96

Summary

Novavax beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.